1. Others
  2. Others

Argipressin (Synonyms: Vasopressin; Arg8-vasopressin; AVP)

Cat. No.: HY-P0049 Purity: 99.66%
Data Sheet SDS Handling Instructions

Argipressin is a Antidiuretic hormone that has been found in most mammalian species.

For research use only. We do not sell to patients.
Argipressin Chemical Structure

Argipressin Chemical Structure

CAS No. : 113-79-1

Size Price Stock Quantity
10 mM * 1 mL in Water $143 In-stock
1 mg $50 In-stock
5 mg $90 In-stock
10 mg $120 In-stock
25 mg $160 In-stock
50 mg $190 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Top Publications Citing Use of Products
  • Biological Activity

  • Technical Information

  • Purity & Documentation

  • References

Description

Argipressin is a Antidiuretic hormone that has been found in most mammalian species. Also acts as a neurotransmitter at synapses in the brain; increases [Ca2+]i in cultured rat hippocampal neurons.

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01324232 Avanir Pharmaceuticals Central Neuropathic Pain|Multiple Sclerosis September 2011 Phase 2
NCT02402595 Avanir Pharmaceuticals Healthy March 2015 Phase 1
NCT02336347 Avanir Pharmaceuticals Healthy Volunteer May 2014 Phase 1
NCT02477670 Avanir Pharmaceuticals Schizophrenia September 2015 Phase 2
NCT02174822 Avanir Pharmaceuticals Drug-drug Interaction January 2014 Phase 1
NCT02446132 Avanir Pharmaceuticals Agitation in Patients With Dementia of the Alzheimer's Type December 2015 Phase 3
NCT02174835 Avanir Pharmaceuticals Healthy September 2013 Phase 1
NCT02153502 Avanir Pharmaceuticals Depressive Disorder, Treatment-Resistant July 2014 Phase 2
NCT01202695 Emergent BioSolutions|National Institutes of Health (NIH) Anthrax August 2010 Phase 1
NCT00021697 Avanir Pharmaceuticals Amyotrophic Lateral Sclerosis January 2001 Phase 3
NCT03095066 Avanir Pharmaceuticals Neurobehavioral Disinhibition May 30, 2017 Phase 2
NCT01767129 Avanir Pharmaceuticals|Michael J. Fox Foundation for Parkinson's Research Dyskinesia|Parkinson's Disease July 2013 Phase 2
NCT00056524 Avanir Pharmaceuticals Alzheimer's Disease|Stroke|Parkinson's Disease|Traumatic Brain Injury February 2003 Phase 3
NCT02534038 Avanir Pharmaceuticals Disinhibition Syndrome December 2015 Phase 2
NCT01584440 Avanir Pharmaceuticals Agitation|Alzheimer's Disease June 2012 Phase 2
NCT02442765 Avanir Pharmaceuticals Agitation in Patients With Dementia of the Alzheimer's Type September 2015 Phase 3
NCT02442778 Avanir Pharmaceuticals Agitation in Patients With Dementia of the Alzheimer's Type September 2015 Phase 3
NCT02205073 Hoffmann-La Roche Healthy Volunteer July 2014 Phase 1
NCT01787747 Avanir Pharmaceuticals Healthy October 2012 Phase 1
NCT00050232 Avanir Pharmaceuticals Multiple Sclerosis December 2002 Phase 3
NCT00748072 University of Bari Kidney Failure August 2008 Phase 4
NCT01566539 Emory University|National Institute of Mental Health (NIMH)|John Templeton Foundation Healthy April 2008
NCT02068560 University of Aarhus|Ferring Pharmaceuticals Gender Difference in V2 Receptor Function in Response to dDAVP Infusion|Nocturia|Nocturnal Enuresis May 2012
NCT00337766 Università Vita-Salute San Raffaele Hemorrhage|Blood Loss, Surgical|Postoperative Hemorrhage June 2006 Phase 4
NCT03136003 The Hospital for Sick Children|Canadian Hemophilia Society|St. Michael's Hospital, Toronto Children With Mild Hemophilia A July 2017 Phase 4
NCT01982760 University Hospitals Cleveland Medical Center Postoperative Ecchymosis December 2013 Phase 2
NCT01534117 Chang, Steve S., M.D.|Santa Barbara Cottage Hospital|Accumetrics, Inc. Head Injury Trauma Blunt October 2009
NCT00961532 Northwestern University|Northwestern Memorial Hospital Intracerebral Hemorrhage December 2010 Phase 2
NCT00835211 Teva Pharmaceuticals USA Healthy July 2003 Phase 1
NCT00223717 Vanderbilt University|Vanderbilt University Medical Center Hypertension June 2001 Phase 1
NCT01324232 Avanir Pharmaceuticals Central Neuropathic Pain|Multiple Sclerosis September 2011 Phase 2
NCT02402595 Avanir Pharmaceuticals Healthy March 2015 Phase 1
NCT02336347 Avanir Pharmaceuticals Healthy Volunteer May 2014 Phase 1
NCT02477670 Avanir Pharmaceuticals Schizophrenia September 2015 Phase 2
NCT02174822 Avanir Pharmaceuticals Drug-drug Interaction January 2014 Phase 1
NCT02446132 Avanir Pharmaceuticals Agitation in Patients With Dementia of the Alzheimer's Type December 2015 Phase 3
NCT02174835 Avanir Pharmaceuticals Healthy September 2013 Phase 1
NCT02153502 Avanir Pharmaceuticals Depressive Disorder, Treatment-Resistant July 2014 Phase 2
NCT01202695 Emergent BioSolutions|National Institutes of Health (NIH) Anthrax August 2010 Phase 1
NCT00021697 Avanir Pharmaceuticals Amyotrophic Lateral Sclerosis January 2001 Phase 3
NCT03095066 Avanir Pharmaceuticals Neurobehavioral Disinhibition May 30, 2017 Phase 2
NCT01767129 Avanir Pharmaceuticals|Michael J. Fox Foundation for Parkinson's Research Dyskinesia|Parkinson's Disease July 2013 Phase 2
NCT00056524 Avanir Pharmaceuticals Alzheimer's Disease|Stroke|Parkinson's Disease|Traumatic Brain Injury February 2003 Phase 3
NCT02534038 Avanir Pharmaceuticals Disinhibition Syndrome December 2015 Phase 2
NCT01584440 Avanir Pharmaceuticals Agitation|Alzheimer's Disease June 2012 Phase 2
NCT02442765 Avanir Pharmaceuticals Agitation in Patients With Dementia of the Alzheimer's Type September 2015 Phase 3
NCT02442778 Avanir Pharmaceuticals Agitation in Patients With Dementia of the Alzheimer's Type September 2015 Phase 3
NCT02205073 Hoffmann-La Roche Healthy Volunteer July 2014 Phase 1
NCT01787747 Avanir Pharmaceuticals Healthy October 2012 Phase 1
NCT00050232 Avanir Pharmaceuticals Multiple Sclerosis December 2002 Phase 3
NCT00748072 University of Bari Kidney Failure August 2008 Phase 4
NCT01566539 Emory University|National Institute of Mental Health (NIMH)|John Templeton Foundation Healthy April 2008
NCT02068560 University of Aarhus|Ferring Pharmaceuticals Gender Difference in V2 Receptor Function in Response to dDAVP Infusion|Nocturia|Nocturnal Enuresis May 2012
NCT00337766 Università Vita-Salute San Raffaele Hemorrhage|Blood Loss, Surgical|Postoperative Hemorrhage June 2006 Phase 4
NCT03136003 The Hospital for Sick Children|Canadian Hemophilia Society|St. Michael's Hospital, Toronto Children With Mild Hemophilia A July 2017 Phase 4
NCT01982760 University Hospitals Cleveland Medical Center Postoperative Ecchymosis December 2013 Phase 2
NCT01534117 Chang, Steve S., M.D.|Santa Barbara Cottage Hospital|Accumetrics, Inc. Head Injury Trauma Blunt October 2009
NCT00961532 Northwestern University|Northwestern Memorial Hospital Intracerebral Hemorrhage December 2010 Phase 2
NCT00835211 Teva Pharmaceuticals USA Healthy July 2003 Phase 1
NCT00223717 Vanderbilt University|Vanderbilt University Medical Center Hypertension June 2001 Phase 1
NCT00628550 University of Texas Southwestern Medical Center|Children's Medical Center Dallas Cardiopulmonary Arrest|Cardiac Arrest April 2008 Phase 1
NCT01393704 Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|North Shore Medical Center|Cedars-Sinai Medical Center Blood Loss, Surgical July 2011 Phase 4
NCT02377492 University Hospitals Cleveland Medical Center Myoma March 2015
NCT00886262 Medical University of South Carolina|Emory University Liver Failure July 2007
NCT02053675 Federal University of São Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo Septic Shock May 2008
NCT00599560 Osaka University|Osaka City University Meniere Disease April 1998
NCT01611935 University of Pennsylvania|National Trauma Research Institute|United States Department of Defense Traumatic Shock May 1, 2013 Phase 2
NCT00379522 Volker Wenzel|Medical University Innsbruck Shock|Hypovolemia|Hemorrhagic Shock July 2010 Phase 2|Phase 3
NCT02975999 Advocate Health Care Pleural Effusion|Single-ventricle December 2016 Phase 2|Phase 3
NCT02394054 University of California, Los Angeles Social Psychology January 2015 Early Phase 1
NCT01327027 Bowdoin College|Maine Medical Center Healthy September 2011 Phase 2
NCT02993640 Sahlgrenska University Hospital, Sweden Portal Blood Pressure|Liver Surgery|Hepatic Hemodynamics September 2016
NCT02454348 University of Arkansas Shock, Septic November 2015 Phase 4
NCT00358579 Singapore General Hospital|National Medical Research Council (NMRC), Singapore|Alexandra Hospital, Singapore|National University Hospital, Singapore|Changi General Hospital Cardiac Arrest March 2006 Phase 3
NCT03088345 Medical College of Wisconsin Circulatory Perfusion Disorder|Congenital Heart Disease|Single-ventricle March 6, 2017 Phase 2|Phase 3
NCT01318278 Baylor College of Medicine|Thrasher Research Fund Hypotension March 2011
NCT00799292 Ascher-Walsh, Charles, M.D. Blood Loss During Vaginal Hysterectomy January 2004 Phase 4
NCT01962870 Stanford University|National Institute of Mental Health (NIMH) Autism Spectrum Disorders October 2013 Phase 2
NCT01247090 Anjali Ganda, MD|Columbia University Hypertension|End Stage Renal Disease October 2010 Phase 2
NCT01718613 Instituto do Cancer do Estado de São Paulo Septic Shock November 2012 Phase 3
NCT01296269 Hadassah Medical Organization|Hebrew University of Jerusalem Healthy April 2011
NCT03204786 Stanford University|National Institutes of Health (NIH) Autism|Autism Spectrum Disorder|ASD July 2017 Phase 2
NCT00795366 University of Miami Traumatic Brain Injury September 2008
NCT01861015 CHA University Uterine Myomas May 2013 Phase 3
NCT02526914 David Mankuta|Hebrew University of Jerusalem|Hadassah Medical Organization Healthy October 2015
NCT00269685 Université de Sherbrooke Shock, Septic July 2000 Phase 2|Phase 3
NCT00411879 University of Athens Heart Arrest June 2006 Phase 2
NCT01370096 University of Alberta Pulmonary Hypertension February 2012 Phase 2
NCT01687894 Chonnam National University Hospital|Chonnam National University Rotator Cuff Tear Arthropathy May 2012
NCT01700478 University Hospital of the West Indies Hemorrhage February 2005 Phase 4
NCT03191240 Asan Medical Center Out-of-Hospital Cardiac Arrest July 1, 2017 Phase 2
NCT01505231 University of Sao Paulo Shock January 2012 Phase 3
NCT00420407 The University of Texas Health Science Center at San Antonio Injuries|Shock, Traumatic February 2007
NCT00127907 Hospices Civils de Lyon Cardiac Arrest May 2004 Phase 4
NCT00729794 University of Athens|University of Thessaly Cardiac Arrest September 2008 Phase 3
NCT00032747 Sanofi Chronic Heart Failure August 2001 Phase 2
NCT00995839 University of Roma La Sapienza Septic Shock|Sepsis November 2008 Phase 2|Phase 3
NCT01493102 Samsung Medical Center Septic Shock December 2011
NCT00481572 University of Roma La Sapienza Septic Shock January 2007 Phase 2
NCT02084797 Oakland University|Georgetown University Electrolyte Imbalance|Hyponatremia|Hypernatremia June 2011
NCT02785224 University of Athens|University of Thessaly Cardiac Arrest May 2017
NCT01680718 University of California, Los Angeles Social Psychology October 2012 Early Phase 1
NCT02118467 University of Chicago Shock May 2014 Phase 4
NCT02223429 James K. Rilling, PhD|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Emory University Healthy August 2014
NCT02675868 Radboud University Endotoxemia January 2016 Phase 4
NCT01093768 National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC) Autism Spectrum Disorders February 19, 2010 Phase 1
NCT01606384 Sanofi Major Depressive Disorder December 2006 Phase 2
NCT00816751 University of California, San Diego Abortion, Induced|Pain December 2007
NCT00624650 Oregon Health and Science University|Pulsion Medical Systems|Oregon Clinical and Translational Research Institute Acute Lung Injury February 2008 Phase 2
NCT02726620 Vanderbilt University Medical Center|UMC Utrecht Hypotension January 2017
View MoreCollapse
References
M.Wt

1084.23

Formula

C₄₆H₆₅N₁₅O₁₂S₂

CAS No.

113-79-1

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

H2O: ≥ 360 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Argipressin
Cat. No.:
HY-P0049
Quantity: